Advantages of adding Metformin to Chemotherapy in Breast Cancer Patients
Phase 3
- Conditions
- Health Condition 1: null- Carcinoma Breast
- Registration Number
- CTRI/2018/03/012810
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All non-diabetic Breast cancer women with BMI more than 22 planned for Neoadjuvant chemotherapy
Exclusion Criteria
Patients with Renal disease, Hepatic disease, alcohol abuse, psychiatric disorder, pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of adding metformin to neo-adjuvant chemotherapy in Breast Cancer patientsTimepoint: 7 months after starting NACT
- Secondary Outcome Measures
Name Time Method 1.To establish safety and tolerance of metformin as a neo-adjuvant drug in Breast cancer. <br/ ><br>2.To measure the effect of metformin on sex hormones. <br/ ><br>3.To study the tumor response to Metformin using Ki67 level <br/ ><br>4.To assess the effect of Metformin on insulin resistance <br/ ><br>Timepoint: 1) 1 week after last cycle of NACT <br/ ><br>2) 7 months after start of NACT